As part of its advocacy program in the United States, ACRO submits regulatory comments to US regulators. This comment letter, submitted by ACRO to FDA in 2024 about Enhancing Adoption of Innovative Clinical Trial Approaches can be found below.
As part of its advocacy program in the United States, ACRO submits regulatory comments to US regulators. This comment letter, submitted by ACRO to FDA in 2024 about Enhancing Adoption of Innovative Clinical Trial Approaches can be found below.